Jane Jardine
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jane Jardine has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Kallinos
Department of Molecular Physiology and Cell Signaling, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK 1
3 shared publications Kilian Trillet
CRCINA: Centre de Recherche en Cancerologie et Immunologie Integree Nantes Angers
3 shared publications- Michael J. Clague
Biochemistry, Cell and Systems Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool
3 shared publications - Nicolas Bidère
CRCI2NA, Nantes Université, INSERM, CNRS, Université d’Angers, Nantes, France
3 shared publications - Sylvie Urbé
Biochemistry, Cell and Systems Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool
3 shared publications - Aitor Martinez
Department of Biochemistry and Molecular Biology, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain
2 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Springer Nature in Research Square
Molecular glue degraders of CK1α remodel lysosomes and limit ferroptosis in glioblastoma stem-like cells
Glioblastoma stem-like cells (GSCs) are highly plastic tumor cells that drive initiation, progression and therapeutic resistance. Although lysosomal homeostasis has emerged as a critical determinant of GSC fitness, the molecular mechanisms regulating this compartment remain incompletely understood. Here, using complementary proteomic approaches, we identified a lysosomal signature associated with the kinase CK1α in THP1 monocytic cells. Biochemical analyses revealed that genetic or siRNA-mediated depletion of CK1α altered the overall abundance and maturation of late endosome-lysosome-associated proteins in both THP1 cells and two patient-derived GSCs. This lysosomal remodeling was associated with impaired tumorsphere formation capacity in GSCs. To further explore the therapeutic potential of targeting CK1α, we employed selective molecular glue degraders (MGDs). Acute CK1α degradation efficiently recapitulated lysosomal remodeling and impaired tumorsphere formation in GSCs. While CK1α-targeted MGDs did not sensitize GSCs to lysosomal membrane permeabilization induced by L-leucyl-L-leucine methyl ester (LLOMe), they protected from GPX4 inhibitor-induced ferroptosis. Together, these findings identify CK1α as a regulator of lysosomal fitness and ferroptotic sensitivity, suggesting a connection between CK1α-dependent lysosome remodeling and associated cell death pathways.
- 13 November 2026
- Published by Springer Nature in Research Square
Open AccessMolecular glue degraders of CK1α remodel lysosomes and limit ferroptosis in glioblastoma stem-like cells
Glioblastoma stem-like cells (GSCs) are highly plastic tumor cells that drive initiation, progression and therapeutic resistance. Although lysosomal homeostasis has emerged as a critical determinant of GSC fitness, the molecular mechanisms regulating this compartment remain incompletely understood. Here, using complementary proteomic approaches, we identified a lysosomal signature associated with the kinase CK1α in THP1 monocytic cells. Biochemical analyses revealed that genetic or siRNA-mediated depletion of CK1α altered the overall abundance and maturation of late endosome-lysosome-associated proteins in both THP1 cells and two patient-derived GSCs. This lysosomal remodeling was associated with impaired tumorsphere formation capacity in GSCs. To further explore the therapeutic potential of targeting CK1α, we employed selective molecular glue degraders (MGDs). Acute CK1α degradation efficiently recapitulated lysosomal remodeling and impaired tumorsphere formation in GSCs. While CK1α-targeted MGDs did not sensitize GSCs to lysosomal membrane permeabilization induced by L-leucyl-L-leucine methyl ester (LLOMe), they protected from GPX4 inhibitor-induced ferroptosis. Together, these findings identify CK1α as a regulator of lysosomal fitness and ferroptotic sensitivity, suggesting a connection between CK1α-dependent lysosome remodeling and associated cell death pathways.
- Open Access
Molecular glue degraders of CK1α remodel lysosomes and limit ferroptosis in glioblastoma stem-like cells
Glioblastoma stem-like cells (GSCs) are highly plastic tumor cells that drive initiation, progression and therapeutic resistance. Although lysosomal homeostasis has emerged as a critical determinant of GSC fitness, the molecular mechanisms regulating this compartment remain incompletely understood. Here, using complementary proteomic approaches, we identified a lysosomal signature associated with the kinase CK1α in THP1 monocytic cells. Biochemical analyses revealed that genetic or siRNA-mediated depletion of CK1α altered the overall abundance and maturation of late endosome-lysosome-associated proteins in both THP1 cells and two patient-derived GSCs. This lysosomal remodeling was associated with impaired tumorsphere formation capacity in GSCs. To further explore the therapeutic potential of targeting CK1α, we employed selective molecular glue degraders (MGDs). Acute CK1α degradation efficiently recapitulated lysosomal remodeling and impaired tumorsphere formation in GSCs. While CK1α-targeted MGDs did not sensitize GSCs to lysosomal membrane permeabilization induced by L-leucyl-L-leucine methyl ester (LLOMe), they protected from GPX4 inhibitor-induced ferroptosis. Together, these findings identify CK1α as a regulator of lysosomal fitness and ferroptotic sensitivity, suggesting a connection between CK1α-dependent lysosome remodeling and associated cell death pathways.
Open AccessMolecular glue degraders of CK1α remodel lysosomes and limit ferroptosis in glioblastoma stem-like cells
Glioblastoma stem-like cells (GSCs) are highly plastic tumor cells that drive initiation, progression and therapeutic resistance. Although lysosomal homeostasis has emerged as a critical determinant of GSC fitness, the molecular mechanisms regulating this compartment remain incompletely understood. Here, using complementary proteomic approaches, we identified a lysosomal signature associated with the kinase CK1α in THP1 monocytic cells. Biochemical analyses revealed that genetic or siRNA-mediated depletion of CK1α altered the overall abundance and maturation of late endosome-lysosome-associated proteins in both THP1 cells and two patient-derived GSCs. This lysosomal remodeling was associated with impaired tumorsphere formation capacity in GSCs. To further explore the therapeutic potential of targeting CK1α, we employed selective molecular glue degraders (MGDs). Acute CK1α degradation efficiently recapitulated lysosomal remodeling and impaired tumorsphere formation in GSCs. While CK1α-targeted MGDs did not sensitize GSCs to lysosomal membrane permeabilization induced by L-leucyl-L-leucine methyl ester (LLOMe), they protected from GPX4 inhibitor-induced ferroptosis. Together, these findings identify CK1α as a regulator of lysosomal fitness and ferroptotic sensitivity, suggesting a connection between CK1α-dependent lysosome remodeling and associated cell death pathways.
- Open Access
- 24 March 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (5)
DNA-PK interacts with cyclic dinucleotides and inhibits type I interferon responses
Inflammatory signal termination is critical for the maintenance of homeostasis. Cyclic dinucleotides (CDNs) are second messengers that trigger inflammatory responses through the activation of the stimulator of IFN genes (STING) signaling platform. No broad-acting direct regulator of intracellular CDNs has been identified in mammals to date. We show that the DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a major DNA damage response actor, directly interacts with the intracellular 2′3′-cGAMP CDN through its kinase domain, tempering STING activation. DNA-PKcs also acts on the 3′3′-cGAMP bacterial CDN and pharmacological STING agonists, impacting their bioactivity and ability to mount optimal antiviral responses. STING agonism has been considered as a therapeutic avenue to alleviate immunosuppression in human pathologies. By uncovering DNA-PKcs as a CDN signaling modulator and CDNs as inhibitors of DNA-PKcs kinase activity, we provide critical insights into CDN regulation, with implications for the development of STING-targeting therapeutics.
- 24 March 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (5)
Open AccessDNA-PK interacts with cyclic dinucleotides and inhibits type I interferon responses
Inflammatory signal termination is critical for the maintenance of homeostasis. Cyclic dinucleotides (CDNs) are second messengers that trigger inflammatory responses through the activation of the stimulator of IFN genes (STING) signaling platform. No broad-acting direct regulator of intracellular CDNs has been identified in mammals to date. We show that the DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a major DNA damage response actor, directly interacts with the intracellular 2′3′-cGAMP CDN through its kinase domain, tempering STING activation. DNA-PKcs also acts on the 3′3′-cGAMP bacterial CDN and pharmacological STING agonists, impacting their bioactivity and ability to mount optimal antiviral responses. STING agonism has been considered as a therapeutic avenue to alleviate immunosuppression in human pathologies. By uncovering DNA-PKcs as a CDN signaling modulator and CDNs as inhibitors of DNA-PKcs kinase activity, we provide critical insights into CDN regulation, with implications for the development of STING-targeting therapeutics.
- 14 March 2025
- Published by Wiley in The FEBS Journal
- Vol. 292 (10) , 2506-2510
How to promote co‐development between postdocs: a case for peer group meetings
‘Who in their right mind would add another meeting to an already overflowing schedule?’ This thought crossed our minds when we first discussed the idea of a postdoc peer group meeting. We are five early career researchers working in the same laboratory, each from a different background, shaped as much by our origins, stages in life, and previous research experience. When we started our series of meetings by asking ‘What is a postdoc?’, we struggled with our own definition of the position, bringing different answers and perspectives. This made us realize that postdoc peer group meetings could be a journey toward open discussion, co‐development, and self‐discovery.
- 14 March 2025
- Published by Wiley in The FEBS Journal
- Vol. 292 (10) , 2506-2510
How to promote co‐development between postdocs: a case for peer group meetings
‘Who in their right mind would add another meeting to an already overflowing schedule?’ This thought crossed our minds when we first discussed the idea of a postdoc peer group meeting. We are five early career researchers working in the same laboratory, each from a different background, shaped as much by our origins, stages in life, and previous research experience. When we started our series of meetings by asking ‘What is a postdoc?’, we struggled with our own definition of the position, bringing different answers and perspectives. This made us realize that postdoc peer group meetings could be a journey toward open discussion, co‐development, and self‐discovery.
- Open Access
DNA-PK interacts with cyclic dinucleotides and inhibits type I Interferon responses
Cytosolic dsDNAs are potent immune-stimulatory molecules that trigger inflammation in several human pathologies 1,2. A major pathway for the detection of cytosolic dsDNA relies on the cyclic GMP-AMP (cGAMP) synthase (cGAS) that produces the 2’3’-cGAMP cyclic dinucleotide (CDN) for activation of the Stimulator of Interferon Genes (STING) adaptor protein that subsequently drives type I Interferon (IFN) responses 3,4. Here, we investigated the mechanism regulating intracellular 2’3’-cGAMP levels. We show that the DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a major player in the repair of double-strand breaks, directly regulates intracellular levels of 2’3’-cGAMP, thereby reducing STING activation. We describe that the binding of 2’3’-cGAMP to DNA-PKcs occurs in its catalytic cleft, impeding its kinase function. Contrary to other CDN regulatory mechanisms that have been shown to primarily regulate extracellular 2’3’-cGAMP, we show that DNA-PKcs also interacts with the 3’3’-cGAMP bacterial CDN, limiting its capacity to activate STING signaling. Furthermore, we found that DNA-PKcs decreases the potency of pharmacological STING activators. As STING is a major target for therapeutic interventions aiming to boost inflammatory responses in immunosuppressed contexts 5, our data bear important implications for drug development and deepens our understanding of inflammatory regulation in response to CDNs.
Open AccessDNA-PK interacts with cyclic dinucleotides and inhibits type I Interferon responses
Cytosolic dsDNAs are potent immune-stimulatory molecules that trigger inflammation in several human pathologies 1,2. A major pathway for the detection of cytosolic dsDNA relies on the cyclic GMP-AMP (cGAMP) synthase (cGAS) that produces the 2’3’-cGAMP cyclic dinucleotide (CDN) for activation of the Stimulator of Interferon Genes (STING) adaptor protein that subsequently drives type I Interferon (IFN) responses 3,4. Here, we investigated the mechanism regulating intracellular 2’3’-cGAMP levels. We show that the DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a major player in the repair of double-strand breaks, directly regulates intracellular levels of 2’3’-cGAMP, thereby reducing STING activation. We describe that the binding of 2’3’-cGAMP to DNA-PKcs occurs in its catalytic cleft, impeding its kinase function. Contrary to other CDN regulatory mechanisms that have been shown to primarily regulate extracellular 2’3’-cGAMP, we show that DNA-PKcs also interacts with the 3’3’-cGAMP bacterial CDN, limiting its capacity to activate STING signaling. Furthermore, we found that DNA-PKcs decreases the potency of pharmacological STING activators. As STING is a major target for therapeutic interventions aiming to boost inflammatory responses in immunosuppressed contexts 5, our data bear important implications for drug development and deepens our understanding of inflammatory regulation in response to CDNs.
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (18) , 1543-1555
CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma
A strategy combining targeted therapies is effective in B-cell lymphomas (BCL), such as mantle cell lymphoma (MCL), but acquired resistances remain a recurrent issue. In this study, we performed integrative longitudinal genomic and single-cell RNA-sequencing analyses of patients with MCL who were treated with targeted therapies against CD20, BCL2, and Bruton tyrosine kinase (OAsIs trial). We revealed the emergence of subclones with a selective advantage against OAsIs combination in vivo and showed that resistant cells were characterized by B-cell receptor (BCR)–independent overexpression of NF-κB1 target genes, especially owing to CARD11 mutations. Functional studies demonstrated that CARD11 gain of function not only resulted in BCR independence but also directly increased the transcription of the antiapoptotic BCL2A1, leading to resistance against venetoclax and OAsIs combination. Based on the transcriptional profile of OAsIs-resistant subclones, we designed a 16-gene resistance signature that was also predictive for patients with MCL who were treated with conventional chemotherapy, underlying a common escape mechanism. Among druggable strategies to inhibit CARD11-dependent NF-κB1 transduction, we evaluated the selective inhibition of its essential partner MALT1. We demonstrated that MALT1 protease inhibition led to a reduction in the expression of genes involved in OAsIs resistance, including BCL2A1. Consequently, MALT1 inhibition induced synergistic cell death in combination with BCL2 inhibition, irrespective of CARD11 mutational status, both in vitro and in vivo. Taken together, our study identified mechanisms of resistance to targeted therapies and provided a novel strategy to overcome resistance in aggressive BCL. The OAsIs trial was registered at www.clinicaltrials.gov #NCT02558816.
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (18) , 1543-1555
CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma
A strategy combining targeted therapies is effective in B-cell lymphomas (BCL), such as mantle cell lymphoma (MCL), but acquired resistances remain a recurrent issue. In this study, we performed integrative longitudinal genomic and single-cell RNA-sequencing analyses of patients with MCL who were treated with targeted therapies against CD20, BCL2, and Bruton tyrosine kinase (OAsIs trial). We revealed the emergence of subclones with a selective advantage against OAsIs combination in vivo and showed that resistant cells were characterized by B-cell receptor (BCR)–independent overexpression of NF-κB1 target genes, especially owing to CARD11 mutations. Functional studies demonstrated that CARD11 gain of function not only resulted in BCR independence but also directly increased the transcription of the antiapoptotic BCL2A1, leading to resistance against venetoclax and OAsIs combination. Based on the transcriptional profile of OAsIs-resistant subclones, we designed a 16-gene resistance signature that was also predictive for patients with MCL who were treated with conventional chemotherapy, underlying a common escape mechanism. Among druggable strategies to inhibit CARD11-dependent NF-κB1 transduction, we evaluated the selective inhibition of its essential partner MALT1. We demonstrated that MALT1 protease inhibition led to a reduction in the expression of genes involved in OAsIs resistance, including BCL2A1. Consequently, MALT1 inhibition induced synergistic cell death in combination with BCL2 inhibition, irrespective of CARD11 mutational status, both in vitro and in vivo. Taken together, our study identified mechanisms of resistance to targeted therapies and provided a novel strategy to overcome resistance in aggressive BCL. The OAsIs trial was registered at www.clinicaltrials.gov #NCT02558816.
- Open Access
- 7 July 2020
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 3 (8) , e202000768
USP30 sets a trigger threshold for PINK1–PARKIN amplification of mitochondrial ubiquitylation
The mitochondrial deubiquitylase USP30 negatively regulates the selective autophagy of damaged mitochondria. We present the characterisation of an N-cyano pyrrolidine compound, FT3967385, with high selectivity for USP30. We demonstrate that ubiquitylation of TOM20, a component of the outer mitochondrial membrane import machinery, represents a robust biomarker for both USP30 loss and inhibition. A proteomics analysis, on a SHSY5Y neuroblastoma cell line model, directly compares the effects of genetic loss of USP30 with chemical inhibition. We have thereby identified a subset of ubiquitylation events consequent to mitochondrial depolarisation that are USP30 sensitive. Within responsive elements of the ubiquitylome, several components of the outer mitochondrial membrane transport (TOM) complex are prominent. Thus, our data support a model whereby USP30 can regulate the availability of ubiquitin at the specific site of mitochondrial PINK1 accumulation following membrane depolarisation. USP30 deubiquitylation of TOM complex components dampens the trigger for the Parkin-dependent amplification of mitochondrial ubiquitylation leading to mitophagy. Accordingly, PINK1 generation of phospho-Ser65 ubiquitin proceeds more rapidly in cells either lacking USP30 or subject to USP30 inhibition.
- 7 July 2020
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 3 (8) , e202000768
Open AccessUSP30 sets a trigger threshold for PINK1–PARKIN amplification of mitochondrial ubiquitylation
The mitochondrial deubiquitylase USP30 negatively regulates the selective autophagy of damaged mitochondria. We present the characterisation of an N-cyano pyrrolidine compound, FT3967385, with high selectivity for USP30. We demonstrate that ubiquitylation of TOM20, a component of the outer mitochondrial membrane import machinery, represents a robust biomarker for both USP30 loss and inhibition. A proteomics analysis, on a SHSY5Y neuroblastoma cell line model, directly compares the effects of genetic loss of USP30 with chemical inhibition. We have thereby identified a subset of ubiquitylation events consequent to mitochondrial depolarisation that are USP30 sensitive. Within responsive elements of the ubiquitylome, several components of the outer mitochondrial membrane transport (TOM) complex are prominent. Thus, our data support a model whereby USP30 can regulate the availability of ubiquitin at the specific site of mitochondrial PINK1 accumulation following membrane depolarisation. USP30 deubiquitylation of TOM complex components dampens the trigger for the Parkin-dependent amplification of mitochondrial ubiquitylation leading to mitophagy. Accordingly, PINK1 generation of phospho-Ser65 ubiquitin proceeds more rapidly in cells either lacking USP30 or subject to USP30 inhibition.
- 9 June 2019
- Published by Taylor & Francis in Autophagy
- Vol. 15 (9) , 1634-1637
New aspects of USP30 biology in the regulation of pexophagy
Mitochondria and peroxisomes have a number of features in common: they each play interconnected roles in fatty acid and reactive oxygen species (ROS) metabolism and, once damaged, need to be removed by specialized autophagic mechanisms, termed mitophagy and pexophagy, respectively. Both processes can use ubiquitin as an initiating signal but whereas mitophagy has been extensively studied, pexophagy remains rather poorly understood. Our recent work, along with a new study from Kim and colleagues, has shed light on the molecular mechanism of pexophagy and the importance of reversible ubiquitination in its regulation. Collectively, these studies highlight the physiological role of the deubiquitinase USP30 in suppressing the turnover of peroxisomes. Abbreviations: ROS: reactive oxygen species; DUB: deubiquitinase or deubiquitylase; USP: ubiquitin specific protease; PINK1: PTEN induced kinase 1; CAT: catalase; KO: knock-out; SQSTM1/p62: sequestosome 1; LIR: LC3 interacting region; GFP: green fluorescent protein; RFP: red fluorescent protein; CRISPR: Clustered Regularly Interspaced Short Palendromic Repeat
- 9 June 2019
- Published by Taylor & Francis in Autophagy
- Vol. 15 (9) , 1634-1637
New aspects of USP30 biology in the regulation of pexophagy
Mitochondria and peroxisomes have a number of features in common: they each play interconnected roles in fatty acid and reactive oxygen species (ROS) metabolism and, once damaged, need to be removed by specialized autophagic mechanisms, termed mitophagy and pexophagy, respectively. Both processes can use ubiquitin as an initiating signal but whereas mitophagy has been extensively studied, pexophagy remains rather poorly understood. Our recent work, along with a new study from Kim and colleagues, has shed light on the molecular mechanism of pexophagy and the importance of reversible ubiquitination in its regulation. Collectively, these studies highlight the physiological role of the deubiquitinase USP30 in suppressing the turnover of peroxisomes. Abbreviations: ROS: reactive oxygen species; DUB: deubiquitinase or deubiquitylase; USP: ubiquitin specific protease; PINK1: PTEN induced kinase 1; CAT: catalase; KO: knock-out; SQSTM1/p62: sequestosome 1; LIR: LC3 interacting region; GFP: green fluorescent protein; RFP: red fluorescent protein; CRISPR: Clustered Regularly Interspaced Short Palendromic Repeat
- Open Access
- 12 June 2018
- Published by Springer Nature in EMBO Reports
- Vol. 19 (7)
Dual role of USP30 in controlling basal pexophagy and mitophagy
USP30 is an integral protein of the outer mitochondrial membrane that counteracts PINK1 and Parkin‐dependent mitophagy following acute mitochondrial depolarisation. Here, we use two distinct mitophagy reporter systems to reveal tonic suppression by USP30, of a PINK1‐dependent component of basal mitophagy in cells lacking detectable Parkin. We propose that USP30 acts upstream of PINK1 through modulation of PINK1‐substrate availability and thereby determines the potential for mitophagy initiation. We further show that a fraction of endogenous USP30 is independently targeted to peroxisomes where it regulates basal pexophagy in a PINK1‐ and Parkin‐independent manner. Thus, we reveal a critical role of USP30 in the clearance of the two major sources of ROS in mammalian cells and in the regulation of both a PINK1‐dependent and a PINK1‐independent selective autophagy pathway.
- 12 June 2018
- Published by Springer Nature in EMBO Reports
- Vol. 19 (7)
Open AccessDual role of USP30 in controlling basal pexophagy and mitophagy
USP30 is an integral protein of the outer mitochondrial membrane that counteracts PINK1 and Parkin‐dependent mitophagy following acute mitochondrial depolarisation. Here, we use two distinct mitophagy reporter systems to reveal tonic suppression by USP30, of a PINK1‐dependent component of basal mitophagy in cells lacking detectable Parkin. We propose that USP30 acts upstream of PINK1 through modulation of PINK1‐substrate availability and thereby determines the potential for mitophagy initiation. We further show that a fraction of endogenous USP30 is independently targeted to peroxisomes where it regulates basal pexophagy in a PINK1‐ and Parkin‐independent manner. Thus, we reveal a critical role of USP30 in the clearance of the two major sources of ROS in mammalian cells and in the regulation of both a PINK1‐dependent and a PINK1‐independent selective autophagy pathway.
- 9 March 2017
- Published by Sciencematters in Matters (Zürich)
- Vol. 3 (3)
Folinic acid is neuroprotective in a fly model of Parkinson’s disease associated with pink1 mutations
Matters is a next-generation science journal. Mutations in PTEN-induced kinase 1 (PINK1) cause autosomal recessive and early-onset Parkinson’s disease (PD). PINK1, a kinase involved in a mitochondrial quality control mechanism, acts by promoting the autophagic degradation of damaged mitochondria. Mutations in PINK1 lead to the accumulation of impaired mitochondria and the death of dopaminergic neurons. Folates act as single carbon donors in metabolic reactions such as nucleotide synthesis from purines. Oral folates are available in two forms, folic and folinic acid (FA and FiA, respectively). In Drosophila pink1 mutants, enhancing nucleotide biosynthesis via dietary supplementation with FA during development rescues mitochondrial function and leads to neuroprotection in adults. Orally available FiA bypasses the deconjugation and reduction steps required with FA and is more metabolically active. Here, we investigated the neuroprotective potential of dietary supplementation with FiA in adult pink1 mutant flies. We show that an FiA-enriched diet begun at early to middle stages of adulthood prevents the degeneration of dopaminergic neurons observed in pink1 mutants. An FiA-enriched diet might therefore delay or prevent the neuronal loss in patients with PINK1 mutations and may ameliorate other diseases linked to mitochondrial defects.
- 9 March 2017
- Published by Sciencematters in Matters (Zürich)
- Vol. 3 (3)
Folinic acid is neuroprotective in a fly model of Parkinson’s disease associated with pink1 mutations
Matters is a next-generation science journal. Mutations in PTEN-induced kinase 1 (PINK1) cause autosomal recessive and early-onset Parkinson’s disease (PD). PINK1, a kinase involved in a mitochondrial quality control mechanism, acts by promoting the autophagic degradation of damaged mitochondria. Mutations in PINK1 lead to the accumulation of impaired mitochondria and the death of dopaminergic neurons. Folates act as single carbon donors in metabolic reactions such as nucleotide synthesis from purines. Oral folates are available in two forms, folic and folinic acid (FA and FiA, respectively). In Drosophila pink1 mutants, enhancing nucleotide biosynthesis via dietary supplementation with FA during development rescues mitochondrial function and leads to neuroprotection in adults. Orally available FiA bypasses the deconjugation and reduction steps required with FA and is more metabolically active. Here, we investigated the neuroprotective potential of dietary supplementation with FiA in adult pink1 mutant flies. We show that an FiA-enriched diet begun at early to middle stages of adulthood prevents the degeneration of dopaminergic neurons observed in pink1 mutants. An FiA-enriched diet might therefore delay or prevent the neuronal loss in patients with PINK1 mutations and may ameliorate other diseases linked to mitochondrial defects.